ONE-WAYOngoing theme · still written in the latest filings

Expansion of Cell Culture and Processing Facilities and CDMO Manufacturing Infrastructure

A capital investment theme focused on expanding the manufacturing and processing infrastructure supporting the regenerative medicine CDMO business, including additional cell culture and processing facilities and pilot-scale plants such as CLiC-1 and Nakanoshima Cross.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2023 →Still being written about.

Directionhelps1 helps · 0 hurts · 0 flat